olmesartan medoxomil and amlodipine

ATC code
C09DB02
Therapeutic class
Angiotensin II receptor blocker combined with a calcium-channel blocker · Fixed-dose combination of olmesartan medoxomil and amlodipine
Forms
Oral film-coated tablet
Brand names
Balzak 20 mg/5 mg (ES)
Overall confidence
high

Regulatory sources consulted

Approved indications

Contraindications

Absolute

  • Hypersensitivity to the active substances, dihydropyridine derivatives, or excipients.
  • Second or third trimester of pregnancy.
  • Severe hepatic impairment or biliary obstruction.
  • Severe hypotension, shock, severe left-ventricular outflow obstruction, or unstable heart failure after acute infarction.

Clinical warnings

Drug interactions

Adverse events

Common (≥1%)

Peripheral edema (11.3%) · Headache (5.3%) · Dizziness (4.5%)

Rare but serious

Angioedema · Acute renal failure · Shock or severe hypotension

Pregnancy and lactation

Use is not recommended in the first trimester and is contraindicated in the second and third; switch to an alternative if pregnancy is planned or detected. During breastfeeding, a treatment with better-established safety is preferred.